BodyTel Enters Into First International Distribution Agreement

JACKSONVILLE, Florida--(Business Wire)--BodyTel Scientific Inc. (OTCBB: BDYT), a developer of wireless
telemedical devices, announces today that it has, through its wholly
owned subsidiary BodyTel Europe GmbH, entered into an international
distribution agreement with FourMed Medical Supplies, a well known
distributor of medical supplies in the Middle east. Beginning in the
first quarter of 2008, BodyTel's new partner, FourMed Medical Supplies
(www.fourmed.com ), intends to begin offering BodyTel's blood glucose
monitoring and diabetes management system, GlucoTel(TM), as well as
the PressureTel(TM) blood pressure device and the WeightTel(TM) weight
scale, once available, in eight Arabian countries, with the United
Arab Emirates as its core market (the "Territory"). Pursuant to the
terms of the distribution agreement BodyTel granted FourMed the right
to exclusively market the products of BodyTel in the Territory for a
term of one year. FourMed is also responsible for all distribution,
compliance and marketing costs relating to the sale of the products in
the Territory.

"FourMed has excellent know-how in the targeted markets, as well
as extensive experience in selling diabetes products. We're convinced
that our new partner will play a key role for BodyTel in the coverage
of the entire Arabian market," said Michael Berrendorf, Sales Director
EMEA of BodyTel.

"FourMed Medical Supplies is extremely happy and proud of the
opportunity to introduce BodyTel's products which will help our
patients and medical professionals in their quest for better diabetes
management. This innovative blood glucose monitoring and diabetes
management system will add great value to our region as it has one of
the world's highest incident rate of diabetes. With our understanding
and long term experience, we want to be the leading provider of
BodyTel's telemedical products in the entire Arabian area," said
Mutasem Al Titi, CEO of FourMed.

Stefan Schraps, BodyTel's CEO, agreed, saying, "Our products,
together with FourMed's impressive sales capabilities, have the
potential to become the standard throughout the entire Middle East.
We're delighted with this new partnership."

BodyTel's first market-ready product is the GlucoTel(TM) blood
glucose meter. It is part of the GlucoTel(TM) system, a complete
telemedical blood glucose monitoring and diabetes management system,
supporting patients and doctors in the treatment of diabetes and its
corollary diseases. GlucoTel(TM) electronically measures the blood
sugar level and then sends it via Bluetooth to the patient's cell
phone. After that, the data is automatically transmitted to an online
database via internet connection and stored on a long-term basis. To
facilitate better diabetes management, the patient and any authorized
persons, e.g. healthcare professionals or caregivers, can access the
data via internet at any time using a secure login.

About BodyTel

BodyTel is a German-American telehealth company that specializes
in telemedical monitoring and management systems for chronic diseases.
The company combines its know-how in telecommunications, internet and
medical technology/diagnostics to create new products and services for
the changing needs of global health. BodyTel products are designed not
only to simplify home monitoring by patients, but also to ease the
communication of 'measured body values' to healthcare professionals or
other caregivers by bridging the gap between the patient and the
caregivers instantaneously and in real-time. BodyTel's products -
GlucoTel, PressureTel and WeightTel are each at different stages of
development and approval processes. BodyTel holds a 50% interest in
GlucoTel Scientific Inc. which holds the rights to the GlucoTel(TM)
blood glucose meter technology.

Further information can be found at www.bodytel.com.

Forward Looking Statements

Statements in this news release that are not historical are
forward-looking statements. Forward-looking statements are statements
that are not historical facts and are generally, but not always,
identified by the words "expects," "plans," "anticipates," "believes,"
"intends," "estimates," "projects," "aims," "potential," "goal,"
"objective," "prospective," and similar expressions, or that events or
conditions "will," "would," "may," "can," "could" or "should" occur.
Forward-looking statements in this news release include: that
BodyTel's new partner, FourMed Medical Supplies intends to begin
offering BodyTel's products in eight Arabian countries, and that our
products, together with FourMed's impressive sales capabilities, have
the potential to become the standard throughout the entire Middle
East.

It is important to note that the Company's actual outcomes may
differ materially from those statements contained in this press
release. Factors which may delay or prevent these forward looking
statements from being realized include, but are not limited to those
concerning the timing of regulatory approval or commercialization of
its products or the achievement of any other clinical, regulatory or
product development milestones or other risk factors and matters set
forth in the Company's Annual Report on Form 10-KSB for the year ended
February 28, 2007 and the Company's periodic reports filed with the
SEC. These reports are available on our investor relations website at
www.bodytel.com and on the SEC's website at http://www.sec.gov.
BodyTel undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the
occurrence of unanticipated events.

BodyTel Europe GmbH
Michaela Klinger
+49 (0)5621 96776 11
press@bodytel.com
or
chain relations
Torsten Herrmann
06192/96 166 80
therrmann@chainrelations.de
or
ZA Consulting Inc.
David Zazoff
US Investor Relations
212-505-5976

Copyright Business Wire 2008